Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-242-1600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.97 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions
What is Spero Therapeutics' stock symbol?
Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."
How were Spero Therapeutics' earnings last quarter?
Spero Therapeutics Inc (NASDAQ:SPRO) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.15. The firm earned $1.69 million during the quarter, compared to analyst estimates of $0.84 million. Spero Therapeutics had a negative return on equity of 43.63% and a negative net margin of 1,050.48%. View Spero Therapeutics' Earnings History.
When is Spero Therapeutics' next earnings date?
What price target have analysts set for SPRO?
4 equities research analysts have issued 1-year target prices for Spero Therapeutics' shares. Their predictions range from $9.00 to $30.00. On average, they anticipate Spero Therapeutics' share price to reach $23.50 in the next year. This suggests a possible upside of 98.3% from the stock's current price. View Analyst Price Targets for Spero Therapeutics.
What is the consensus analysts' recommendation for Spero Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spero Therapeutics.
What are Wall Street analysts saying about Spero Therapeutics stock?
Here are some recent quotes from research analysts about Spero Therapeutics stock:
- 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (3/20/2019)
- 2. Cantor Fitzgerald analysts commented, "We rate SPRO Overweight. As the company advances its pipeline toward commercialization, we expect upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations to drive SPRO’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target." (2/26/2019)
Has Spero Therapeutics been receiving favorable news coverage?
Media headlines about SPRO stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spero Therapeutics earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Who are some of Spero Therapeutics' key competitors?
Some companies that are related to Spero Therapeutics include MacroGenics (MGNX), Akebia Therapeutics (AKBA), CannTrust (CNTTF), CannTrust (CTST), Athenex (ATNX), Arvinas (ARVN), Rocket Pharmaceuticals (RCKT), CymaBay Therapeutics (CBAY), Cara Therapeutics (CARA), ArQule (ARQL), Principia Biopharma (PRNB), ChemoCentryx (CCXI), Vital Therapies (VTL), TG Therapeutics (TGTX) and Evolus (EOLS).
What other stocks do shareholders of Spero Therapeutics own?
Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the folowing people:
- Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)
- Mr. Joel D. Sendek, CFO & Treasurer (Age 52)
- Ms. Cristina Larkin, Chief Operating Officer (Age 49)
- Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)
- Ms. Sharon Klahre, Director of Investor Relations
When did Spero Therapeutics IPO?
(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
Who are Spero Therapeutics' major shareholders?
Spero Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.06%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Institutional Ownership Trends for Spero Therapeutics.
Which major investors are buying Spero Therapeutics stock?
SPRO stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Spero Therapeutics stock in the last two years include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Insider Buying and Selling for Spero Therapeutics.
How do I buy shares of Spero Therapeutics?
Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spero Therapeutics' stock price today?
One share of SPRO stock can currently be purchased for approximately $11.85.
How big of a company is Spero Therapeutics?
Spero Therapeutics has a market capitalization of $204.06 million and generates $3.97 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.
What is Spero Therapeutics' official website?
How can I contact Spero Therapeutics?
Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]
MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
